Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Blood
|
June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Steven Knapper, Abin Thomas, Robert K Hills, et al.
Blood Advances
|
September 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML
Nigel Russell, Jad Othman, Oliver Cumming, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 19, 2024
Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice
Aamer Aleem, Naila A Shaheen, Farjah Algahtani, et al.
Journal of Medical Internet Research
|
October 1, 2020
Adoption of a Personal Health Record in the Digital Age: Cross-Sectional Study
Consuela Cheriece Yousef, Abin Thomas, Ahmed O Alenazi, et al.
JMIR Medical Informatics
|
July 25, 2021
Predicting Patients' Intention to Use a Personal Health Record Using an Adapted Unified Theory of Acceptance and Use of Technology Model: Secondary Data Analysis
Consuela Cheriece Yousef, Teresa M Salgado, Ali Farooq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
BMC Cancer
|
October 25, 2024
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
Margherita Carucci, Andrew Clamp, Cong Zhou, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
The Lancet. Haematology
|
April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials
Nicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Blood Advances
|
September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S Tiong, Richard Dillon, Adam Ivey, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Blood
|
June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Steven Knapper, Abin Thomas, Robert K Hills, et al.
Blood Advances
|
September 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML
Nigel Russell, Jad Othman, Oliver Cumming, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 19, 2024
Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice
Aamer Aleem, Naila A Shaheen, Farjah Algahtani, et al.
Journal of Medical Internet Research
|
October 1, 2020
Adoption of a Personal Health Record in the Digital Age: Cross-Sectional Study
Consuela Cheriece Yousef, Abin Thomas, Ahmed O Alenazi, et al.
JMIR Medical Informatics
|
July 25, 2021
Predicting Patients' Intention to Use a Personal Health Record Using an Adapted Unified Theory of Acceptance and Use of Technology Model: Secondary Data Analysis
Consuela Cheriece Yousef, Teresa M Salgado, Ali Farooq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
BMC Cancer
|
October 25, 2024
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
Margherita Carucci, Andrew Clamp, Cong Zhou, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
The Lancet. Haematology
|
April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials
Nicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Blood Advances
|
September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S Tiong, Richard Dillon, Adam Ivey, et al.
Page
of 5